Effect of Tissue Factor Pathway Inhibitor (TFPI) in the HEPTEST^® Assay and in an Amidolytic Anti Factor Xa Assay for LMW Heparin

Summary

Both the HEPTEST^® and amidolytic anti factor Xa assays are currently being used for heparin activity detection in plasma from patients receiving standard heparin or low molecular weight heparin (LMWH). In this study we have investigated the influence of recombinant and endogenous Tissue Factor Pathway Inhibitor (TFPI) on these assays. The HEPTEST^® determinations were performed on an ACL 300 R Clottimer using the APTT program which resulted in a longer incubation time with factor Xa than recommended by the manufacturer. rTFPI added to plasma prolonged the HEPTEST^® clotting time markedly, but had only a little effect in the amidolytic assay. Antibodies against TFPI (anti-TFPI) abolished these effects. The effect of adding rTFPI and Logiparin^® was additive. When anti-TFPI IgG was added to samples of normal plasma, a statistically significant shortening of the HEPTEST^® clotting time was seen. When anti-TFPI was added to plasma samples from volunteers who had received Logiparin^® by subcutaneous or intravenous injection, then the HEPTEST^® clotting time was shortened considerably. For some samples the clotting time was halved. These experiments show that the HEPTEST^® clotting time is prolonged not only by heparin-antithrombin III, but also by TFPI released by heparin injection.

• References

• 1 Yin ET. A new single stage measurement of heparin by anti-factor Xa. Semin Thromb Hemostas 1985; 11: 243-244
• 2 Bara L, Combe-Tamzali S, Conrad J, Horellow MH, Samama M. Laboratory monitoring of a low molecular weight heparin (Enoxaparin) with a new clotting test (Heptest). Haemostasis 1987; 17: 127-133
• 3 Bara L, Mardiguian J, Samama M. In vitro effect on heptest of low molecular weight heparin fractions and preparations with various anti-IIa and anti-Xa activities. Thromb Res 1990; 57: 585-592
• 4 Halbmayer WM, Feichtinger C, Schwarz T, Gschnait F, Strasser A, Prieshing A, Fisher M. Ein einfacher Test zur Bestimmung der Anti-Xa-Aktivität in Plasmen von Patienten nach subkutaner Gabe von Enoxaparin. Wien Klin Wochenschr 1990; 102: 408-413
• 5 Harenberg J, Giese C, Knödler A, Zimmermann R. Comparative study on a new one stage clotting assay for heparin and its low molecular weight derivatives. Haemostasis 1989; 1: 13-20
• 6 Pedersen PC, Østergaard PB, Hedner U, Bergqvist DMätzsch. Logiparin, after intravenous and subcutaneous administration to healthy volunteers. Thromb Res 1991; 61: 477-487
• 7 Bratt G, Törnebohm E, Widlung LLockner. Low molecular weight heparin (Kabi 2165, Fragmin): Pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986; 42: 613-620
• 8 Bergqvist D, Hedner U, Sjörin E, Holmer E. Anticoagulant effect of two types of low molecular weight heparin administered subcutaneously. Thromb Res 1983; 32: 381-391
• 9 Bratt G, Törnehohm E, Cronqvist S, Åberg N, Lockner D. A comparison between low molecular weight heparin (Kabi 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemostas 1985; 54: 813-817
• 10 Abildgaard U, Norrheim L, Larsen AE, Nesvold A, Sandset PM, Ødegaard OR. Monitoring therapy with LMW heparin: A comparison of three chromogenic substrate assay and the Heptest clotting assay. Hameostasis 1990; 20: 193-203
• 11 Levine MN, Planes A, Hirsh J, Goodyear M, Vochelle N, Gent M. The relationship between anti-factor Xa level and clinical outcome in patients receiving Enoxayparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement. Thromb Haemostas 1989; 62: 940-944
• 12 Broze GJ, Girard TJ, Novotny WF. Regulation of coagulation by a multivalent Kunitz-type inhibitor. Biochemistry 1990; 29: 7539-7546
• 13 Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic pathway inhibitor. Thromb Res 1988; 50: 803-813
• 14 Lindahl AK, Abildgaard U, Stokke G. Release of Extrinsic Pathway Inhibitor after heparin injections: increased response in cancer patients. Thromb Res 1990; 59: 651-656
• 15 Lindahl AK, Abildgaard U, Larsen ML, Aamodt L-M, Nordfang O, Beck TC. Extrinsic Pathway Inhibitor (EPI) and the post-heparin anticoagulant effect in tissue thromboplastin induced coagulation. Thromb Res 1991; 65: 14
• 16 Lindahl AK, Abildgaard U, Larsen ML, Staalesen R, Hammer AKG, Sandset PM, Mordfang O, Beck TC. Extrinsic pathway inhibitor released to the blood by heparin is a more powerful inhibitor than is recombinant TFPI. Thromb Res 1991; 62: 607-614
• 17 Pedersen AH, Nordfang O, Norris F, Wiberg FC, Christensen PM, Moeller KB, Meidahl-Pedersen J, Beck TC, Norris K, Hedner U, Kisiel W. Recombinant human extrinsic pathway inhibitor. J Biol Chem 1990; 265: 16786-16793
• 18 Sandset PM, Abildgaard U, Pettersen M. A sensitive assay of extrinsic pathway inhibitor in plasma and plasma fractions. Thromb Res 1987; 47: 389-400
• 19 Day KC, Hoffman LC, Palmier MO, Kretzmer KK, Huang MD, Pyla EY, Spokas E, Broze GJ, Warren TG, Wun TC. Recombinant lipoprotein-associated coagulation inhibitor inhibits tissue thromboplastin induced intravascular coagulation in the rabbit. Blood 1990; 78: 1538-1545
• 20 Nordfang O, Valentin S, Beck TC, Hedner U. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma. Thromb Haemostas 1991; 66: 464-467
• 21 Wildgoose P, Kisiel W. Activation of human factor VII by factor IXa on human bladder carcinoma cells. Blood 1989; 73: 1888-1895
• 22 Teien AN, Lie M, Abildgaard U. Assay of heparins in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 549-553
• 23 Walenga JM, Hoppensteadt D, Fareed J. Laboratory monitoring of the clinical effects of low molecular weight heparins. Thromb Res 1991; Suppl XIV 49-62
• 24 Valentin S, Østergaard P, Kristensen H, Nordfang O. Simultaneous presence of tissue factor pathway inhibitor (TFPI) and low molecular weight heparin has a synergistic effect in different coagulation assays. Blood Coagulation Fibrinolysis 1991; 2: 629-635
• 25 Wun TC. Lipoprotein-associated coagulation inhibitor (LAC1) is a cofactor for heparin-synergistic anticoagulant action between LAC1 and sulfated polysaccharides. Blood 1992; 79: 430-438
• 26 Lindahl AK, Abildgaard U, Staalesen R. The anticoagulant effect in heparinized blood and plasma resulting from interactions with extrinsic pathway inhibitor. Thromb Res 1991; 64: 155-168
• 27 Nordfang O, Bjørn SE, Valentin S, Nielsen LS, Wildgoose P, Beck TC, Hedner U. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry 1991; 30: 10371-10376